Search

Displaying results 1481 - 1490 of 10000 in total
  1. Drug

    Vanadium

    go.drugbank.com/drugs/DB13971
    Approved

    Mixtures: Doctor's Choice Brand for Men, Multivitamins and Minerals for Men
  2. Drug

    Upadacitinib

    go.drugbank.com/drugs/DB15091
    ApprovedInvestigational

    Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. … More recently, it has also been approved for the treatment of giant cell arteritis in adults and active polyarticular juvenile idiopathic arthritis in patients aged 2 years and older.[L10896]

  3. Drug

    Onasemnogene abeparvovec

    go.drugbank.com/drugs/DB15528
    ApprovedInvestigational

    [L9194] Onasemnogene abeparvovec for therapeutic use and marketing is currently being assessed by the EU and an intrathecal formulation of the drug is currently undergoing clinical development in the USA … Onasemnogene abeparvovec is an adeno-associated virus vector-based gene therapy that has been approved by the FDA in May 2019 for the treatment of infant patients (less than 2 years of age) with spinal

  4. Drug

    Momelotinib

    go.drugbank.com/drugs/DB11763
    ApprovedInvestigational

    MF includes primary MF (PMF), post-polycythemia vera (PV) MF, and post-essential thrombocythemia (ET) MF. Clinical manifestations of MF include anemia and thrombocytosis. … [A261566] First approved by the FDA on September 15, 2023,[L48206] momelotinib is used to treat myelofibrosis.

    Synonyms: N-(CYANOMETHYL)-4-(2-(4-MORPHOLINOANILINO)PYRIMIDIN-4-YL)BENZAMIDE
  5. Drug

    Obeticholic acid

    go.drugbank.com/drugs/DB05990
    ApprovedInvestigational

    Primary biliary cirrhosis, or PBC, is a progressive and chronic condition that leads to hepatic injury often resulting in end-stage liver failure that requires liver transplantation. … The NDA from Intercept Pharmaceuticals was approved in November 2019 and obeticholic acid is expected to be granted full approval for this indication in 2020.[L12636]

  6. Drug

    Tiotropium

    go.drugbank.com/drugs/DB01409
    ApprovedInvestigational

    [A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation. … [A180163] Tiotropium was granted FDA approval on 30 January 2004.[L7084]

  7. Drug

    Motixafortide

    go.drugbank.com/drugs/DB14939
    ApprovedInvestigational

    [A261476] Motixafortide was approved by the FDA in September 2023, in combination with filgrastim, for use in stem cell mobilization prior to autologous stem cell transplant in patients with multiple … [L48116] When administered alongside [filgrastim], another agent used to aid in stem cell collection, motixafortide enabled the collection of an adequate number of stem cells in ~92% of patients within

  8. Drug

    Benzphetamine

    go.drugbank.com/drugs/DB00865
    ApprovedIllicit

    It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222)

    Synonyms: (+)-N-benzyl-N,α-dimethylphenethylamine, (S)-(+)-N-benzyl-N,α-dimethylphenethylamine
  9. Drug

    Trastuzumab deruxtecan

    go.drugbank.com/drugs/DB14962
    ApprovedInvestigational

    [A188988] Trastuzumab deruxtecan was developed by Daiichi Sankyo in collaboration with AstraZeneca and was first approved by the FDA in 2019.[L10842] … [L10842] It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of its class.

  10. Drug

    Omega-3-carboxylic acids

    go.drugbank.com/drugs/DB09568
    ApprovedWithdrawn

    The omega-3 carboxylic acid (OM3-CA) is a new formulation of omega-3 fatty acids that present an enhanced bioavailability in the treatment of dyslipidemia. … [A25808] It was developed by AstraZeneca Pharmaceuticals and firstly approved by the FDA on May 05, 2014.[L2386]